<DOC>
	<DOCNO>NCT00502671</DOCNO>
	<brief_summary>This single arm study evaluate safety profile Xeloda monotherapy adjuvant treatment colon cancer . All patient receive Xeloda 1250mg/m2 p.o . twice daily intermittent treatment ( 3 week cycle consist 2 week treatment follow 1 week without treatment ) . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) Adjuvant Monotherapy Patients With Colon Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; colon cancer ( Dukes stage C ) ; surgery , evidence remain tumor ; ECOG performance status &lt; =1 . previous therapy currently treat colon cancer ; evidence metastatic disease ; history malignancy within last 5 year ; clinically significant cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>